Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP180 siRNA
- Development stage
- Preclinical
- Lead developer
- Inserm
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
BP180 siRNA is a small interfering RNA (siRNA) designed to silence the expression of BP180, also known as Collagen XVII (COL17A1). BP180 is a type II transmembrane protein that serves as a structural component of hemidesmosomes, which mediate the adhesion of epithelial cells to the underlying basement membrane. In certain cancers, such as pancreatic ductal adenocarcinoma, BP180 is aberrantly expressed or cleaved into a pro-migratory form (BP120), facilitating tumor cell invasion and metastasis. By knocking down BP180 expression, this siRNA inhibits the pro-invasive signaling associated with BP180 cleavage and disrupts the assembly of hemidesmosomes, thereby reducing the migratory and invasive potential of cancer cells. It has been utilized in preclinical research to investigate the mechanisms of somatostatin-induced tumor suppression and the role of hemidesmosome assembly in blocking cancer cell invasiveness.
- Other names
- siRNA targeting BP180siRNA targeting Collagen XVIIsiRNA targeting COL17A1COL17A1 siRNACOL-17A1 siRNACOL 17A1 siRNA
02
Targets
COL17A1
Beyond the preview
Go deeper on BP180 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP180 siRNA.